Piper Jaffray Companies Downgrades Amphastar Pharmaceuticals (AMPH) to Neutral
Amphastar Pharmaceuticals (NASDAQ:AMPH) was downgraded by research analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating in a research report issued on Wednesday, MarketBeat reports. They presently have a $23.00 price objective on the stock, down from their previous price objective of $24.00. Piper Jaffray Companies’ target price suggests a potential upside of 12.20% from the company’s current price.
Other equities analysts have also issued research reports about the company. BidaskClub raised Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 3rd. Zacks Investment Research raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. TheStreet raised Amphastar Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Friday, January 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $26.00 price target on shares of Amphastar Pharmaceuticals in a research note on Wednesday, November 14th. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $23.73.
NASDAQ AMPH opened at $20.50 on Wednesday. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of 97.62, a P/E/G ratio of 1.81 and a beta of 1.40. The company has a current ratio of 2.02, a quick ratio of 1.34 and a debt-to-equity ratio of 0.10. Amphastar Pharmaceuticals has a fifty-two week low of $14.40 and a fifty-two week high of $25.43.
In other news, SVP Yakob Liawatidewi sold 3,183 shares of the company’s stock in a transaction on Wednesday, January 16th. The stock was sold at an average price of $22.15, for a total value of $70,503.45. Following the transaction, the senior vice president now owns 37,471 shares of the company’s stock, valued at approximately $829,982.65. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO William J. Peters sold 3,245 shares of the company’s stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $19.52, for a total value of $63,342.40. Following the completion of the transaction, the chief financial officer now directly owns 75,550 shares in the company, valued at approximately $1,474,736. The disclosure for this sale can be found here. In the last ninety days, insiders sold 87,222 shares of company stock worth $2,037,797. Corporate insiders own 31.50% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at $63,000. First Quadrant L P CA acquired a new position in Amphastar Pharmaceuticals during the 4th quarter worth about $67,000. LS Investment Advisors LLC lifted its stake in Amphastar Pharmaceuticals by 217.9% during the 4th quarter. LS Investment Advisors LLC now owns 3,522 shares of the company’s stock worth $70,000 after acquiring an additional 2,414 shares in the last quarter. Quantamental Technologies LLC acquired a new position in Amphastar Pharmaceuticals during the 4th quarter worth about $71,000. Finally, Meeder Asset Management Inc. acquired a new position in Amphastar Pharmaceuticals during the 4th quarter worth about $92,000. 48.22% of the stock is currently owned by institutional investors and hedge funds.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Read More: What is Call Option Volume?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.